2020 Innovation-Based Optimism for Lung Cancer Outcomes

Abstract

Lung cancer is the leading cause of cancer death in both males and females in the U.S. and worldwide. Owing to advances in prevention, screening/early detection, and therapy, lung cancer mortality rates are decreasing and survival rates are increasing. These innovations are based on scientific discoveries in imaging, diagnostics, genomics, molecular therapy, and immunotherapy. Outcomes have improved in all histologies and stages. This review provides information on the clinical implications of these innovations that are practical for the practicing physicians, especially oncologists of all specialities who diagnose and treat patients with lung cancer. Implications for Practice Lung cancer survival rates have improved because of new prevention, screening, and therapy methods. This work provides a review of current standards for each of these areas, including targeted and immunotherapies. Treatment recommendations are provided for all stages of lung cancer.

Hsa_circ_0008133 contributes to lung cancer progression by promoting glycolysis metabolism through the miR‐760/MEX3A axis

“…The prevalence of lung cancer in men is higher than in women, 3 which is related to smoking and long‐term exposure to air pollution 4,5 . With the development of diagnosis, molecular biology, especially targeted therapy, the death rate from lung cancer has decreased 6 . Therefore, this study focuses on exploring new biological targets for the treatment and diagnosis of lung cancer.…”

Identification of fatty acid-related subtypes, the establishment of a prognostic signature, and immune infiltration characteristics in lung adenocarcinoma

“…Approximately 85% of lung cancer incidences are classified as non-small cell lung cancer (NSCLC) [ 2 ]; of these, lung adenocarcinoma (LUAD) represents the predominant histological subtype, constituting nearly 63% of NSCLC cases [ 3 ]. Although the treatment of LUAD has been vastly improved recently, including new immunotherapy, molecular target, and anti-angiogenesis therapy, however, only a small number of patients benefit from them [ 4 , 5 ]. Even with the most sophisticated therapies and advancements, the 5-year survival rate of patients is still less than 15% due to tumor metastasis [ 1 ].…”

International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials

“…1,2 We recently observed a reversal of the trend in lung cancer specific mortality as a consequence of major advances in lung cancer early detection and extensive use of targeted therapies and immunotherapy leading to increased survival. 3,4 These improvements are the end result of a multitude of clinical trials.…”